SR 33805 oxalate

Pricing Availability   Qty
Cat.No. 1806 - SR 33805 oxalate | C32H40N2O5S.C2H2O4 | CAS No. 121346-33-6
Description: Ca2+ channel blocker; binds allosterically to distinct site on L-type channels
Chemical Name: 3,4-Dimethoxy-N-methyl-N-[3-[4-[[1-methyl-3-(1-methylethyl)-1H-indol-2-yl]sulfonyl]phenoxy]propyl]benzeneethanamine
Purity: ≥99% (HPLC)
Datasheet
Citations (1)
Reviews
Literature

Biological Activity

Potent Ca2+ channel antagonist; binds allosterically to the a1-subunit of L-type Ca2+ channels (Kd = 20 pM), at a site distinct from other types of blocker. Shows some selectivity for vascular smooth muscle, inducing vasorelaxation without producing inotropic or chronotropic effects. Inhibits PDGF-stimulated smooth muscle cell proliferation.

Compound Libraries

SR 33805 oxalate is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 654.77
Formula C32H40N2O5S.C2H2O4
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 121346-33-6
PubChem ID 21256218
InChI Key MZWPPDAHWIKZID-UHFFFAOYSA-N
Smiles O=C(O)C(O)=O.O=S(C2=C(C(C)C)C1=CC=CC=C1N2C)(C3=CC=C(OCCCN(C)CCC4=CC=C(OC)C(OC)=C4)C=C3)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 56.47 100

Preparing Stock Solutions

The following data is based on the product molecular weight 654.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.53 mL 7.64 mL 15.27 mL
5 mM 0.31 mL 1.53 mL 3.05 mL
10 mM 0.15 mL 0.76 mL 1.53 mL
50 mM 0.03 mL 0.15 mL 0.31 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References

References are publications that support the biological activity of the product.

Chatelain et al (1993) In vitro characterization of a novel Ca2+ entry blocker: SR 33805. Eur.J.Pharmacol. 246 181 PMID: 8223943

Magnier-Gaubil et al (1996) Smooth muscle cell cycle and proliferation. Relationship between calcium influx and sarco-endoplasmic reticulum Ca2+ATPase regulation. J.Biol.Chem. 271 27788 PMID: 8910375

Romey and Lazdunski (1994) Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J.Pharmacol.Exp.Ther. 271 1348 PMID: 7996445


If you know of a relevant reference for SR 33805 oxalate, please let us know.

View Related Products by Product Action

View all Voltage-gated Calcium Channel (CaV) Blockers

Keywords: SR 33805 oxalate, SR 33805 oxalate supplier, Ca2+, channel, blockers, L-type, Calcium, CaV, Channels, voltage-gated, voltage-dependent, SR33805, oxalate, Voltage-gated, 1806, Tocris Bioscience

1 Citation for SR 33805 oxalate

Citations are publications that use Tocris products. Selected citations for SR 33805 oxalate include:

Wu et al (2008) Coupling of L-type Ca2+ channels to KV7/KCNQ channels creates a novel, activity-dependent, homeostatic intrinsic plasticity. J Neurophysiol 100 1897 PMID: 18715900


Do you know of a great paper that uses SR 33805 oxalate from Tocris? Please let us know.

Reviews for SR 33805 oxalate

There are currently no reviews for this product. Be the first to review SR 33805 oxalate and earn rewards!

Have you used SR 33805 oxalate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Ion Channel

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.